The decision to use a psychotropic medication of any kind during pregnancy or in the postpartum period always requires a careful weighing of the risks and benefits to both the mother and her fetus or newborn. There are several factors that must be considered, including the possible teratogenic effects of the medication, the safety of the medication during labor and delivery, the possible long-term neurobehavioral effects on childhood development, and the effects of ongoing exposure during breastfeeding.
Pregnant and breastfeeding women who experience significant psychiatric illness may need to use benzodiazepines, antipsychotics, mood stabilizers, or other drugs to protect themselves and their infants.
When considering a treatment plan for a pregnant or breastfeeding woman with a psychiatric disorder, the risks to the mother and the fetus or newborn from both the illness and the treatments must be assessed. Medications that should not be used during pregnancy are listed in Table 1. If possible, psychotropic medications in general should be avoided during the first 12 weeks of pregnancy, as this is the time of the most active organ development in the fetus. However, for a woman who is already taking a medication at the time of conception, by the time the pregnancy is confirmed, most or all of the organogenesis has often already occurred. If this is the case, there is wisdom in not panicking. Abrupt discontinuation of medications can precipitate a relapse, and this can result in the need for further medication exposure to stabilize the mother.
Psychotropic medications in pregnancy are indicated for women who develop a significant psychiatric illness during the pregnancy, women who experience an exacerbation of a pre-existing illness during pregnancy, and women who have experienced a rapid deterioration of their condition after discontinuing medication. An international epidemiological survey conducted 12 years ago indicated that the prevalence of psychotropic drug use during pregnancy was approximately 3.5%. At the time, benzodiazepines accounted for the most exposure; however, the increasing use of antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), has made this the most commonly used category of psychotropic medications in pregnancy in recent years. When a medication of any kind is prescribed in pregnancy, the lowest possible dose that will provide complete symptom control should be used. Table 2 outlines the most commonly prescribed psychotropic medications and provides information on their use by pregnant women (see “The use of antidepressants in pregnancy and lactation” elsewhere in this issue for details about SSRI-type medications).
Data on the use of psychotropic medications in breastfeeding women are growing, and recent publications suggest that such medications are not associated with prolonged adverse effects in infants exposed to them through breast milk. However, all psychotropic medications are found in breast milk in varying amounts and are passed on to the nursing infant. Thus, when pharmacotherapy is indicated for a breastfeeding woman, the potential risks of medication exposure in the infant must be weighed against the risks of untreated maternal illness. Table 3 outlines the most commonly prescribed psychotropic medications and provides information on their use by breastfeeding women (see “The use of antidepressants in pregnancy and lactation” elsewhere in this issue for details about SSRI-type medications).
The existing literature on the use of psychotropic medications in pregnant and lactating women is limited to case reports and small studies, making it difficult to formulate any generalizations regarding the safety of these medications. However, the results of studies published to date are promising, with few adverse effects reported. We continue to get information regarding the effects of psychotropic medications from women who conceive while on these drugs. The formation of drug registries and the sharing of information on infant outcomes among clinicians and researchers are essential. In addition, long-term follow-up studies that address possible developmental effects of medication exposure are critical to a better understanding of the safety of psychotropic medication exposure in fetuses and neonates.
Lithium (if possible)
Low-potency typical antipsychotics
|Third trimester and labor and delivery||High-dose benzodiazepines|
|All trimesters||Monoamine oxidase inhibitors (MAOIs)|
• lorazepam (short)
• clonazepam (med)
• alprazolam (short)
• diazepam (long)
|Exposure to high-dose benzodiazepines in utero has been associated with newborn withdrawal symptoms, including irritability and restlessness, apnea, cyanosis, lethargy, and hypotonia. No long-term effects have been reported, although data are limited. Drugs with a short or medium half-life (lorazepam, clonazepam) at the lowest effective doses should be used.|
|Tricyclic antidepressants (TCAs)
|The tricyclic antidepressants are most commonly used for comorbid conditions and when other treatments have failed. TCAs, which were once the treatment of choice for depression and panic, remain effective and are not associated with teratogenesis. Doses may need to be adjusted as the pregnancy proceeds. While data analysis has shown that exposure in pregnancy does not increase the incidence of teratogenesis, neonatal withdrawal symptoms have been associated with these medications, so careful monitoring of the newborn is essential.|
|Monoamine oxidase inhibitors (MAOIs)||The MAOIs are contraindicated in pregnancy, based on animal studies that have reported increased rates of congenital abnormalities.|
|Other non-SSRI antidepressants
|Limited data are available on the use of these medications during pregnancy.||None|
|Low-potency dopamine blockade neuroleptics have been associated with an increased rate of congenital abnormalities. High-potency dopamine blockade antipsychotic medications have not been associated with congenital abnormalities. However, data are limited, and little or no information is available on clozapine, ziprasidone, and quetiapine. Ziprasidone is not yet available in Canada, but to date there are no reports of increased risk with exposure.|
|Low-potency typical antipsychotics (e.g., thioridazine) have been associated with increased risk of mild malformations. High-potency typical antipsychotics (e.g., haloperidol) have not been associated with increased risk.|
• valproic acid
|Limited information is available regarding lamotrigine, topiramate, and gabapentin use in pregnancy. Carbamazepine and valproic acid use during the first trimester has been associated with an increased risk of neural tube defects, as well as minor and major fetal malformations, low birth weight, and thrombocytopenia. Lithium use in pregnancy has been associated with a pronounced increase in the rate of Ebstein anomaly; however, recent literature suggests that this rate is much lower than previously reported (1 in 4000 vs 1 in 400). If lithium is continued in pregnancy, because of the risk of decompensation, drug levels should be monitored carefully. The dose may need to be increased by as much as 100% in pregnancy to maintain symptom control, but should be decreased by at least 50% at the time of delivery to avoid toxicity in both mother and newborn.|
|Case reports indicate that milk plasma concentrations vary from 0.1% to 0.5% of the maternal dose for different benzodiazepines. Sedation, lethargy, impaired respiration, and withdrawal have been reported in exposed infants after prolonged use. Therefore, if these medications are indicated, the minimum dose required for symptom relief should be used, and the infant should be monitored regularly.|
|Tricyclic antidepressants (TCAs)
|The tricyclic antidepressants appear to be safe for use by breastfeeding women. Occasional sedation has been reported in infants exposed to clomipramine and doxepin. The active metabolite of doxepin has the longest half-life of all TCAs, and should be avoided if possible because of the potential for excess accumulation in infant serum. A recent long-term study has reported no adverse developmental effects in infants exposed to TCAs through breast milk.|
|Monoamine oxidase inhibitors (MOAIs)||The MOAIs are not recommended for use by breastfeeding mothers because of profiles indicating extensive interaction with other medications.|
|The long-term developmental effects of neuroleptic exposure on the infant dopamine system and receptors are still unclear. Recent data on haloperidol, olanzapine, and quetiapine are encouraging, with no adverse effects reported. Clozapine has been associated with sedation, irritability, and seizures in infants. There are limited data available on the other atypical neuroleptics, thus caution is recommended.|
• valproic acid
|Lithium has been reported to cross into breast milk at approximately 40% to 50% of the maternal levels. The use of lithium during lactation is contraindicated because the neonatal kidney is still immature and the risk for lithium accumulation is high. Low serum levels have been detected in infants exposed to carbamazepine and valproate through breast milk, suggesting that these drugs are compatible with breastfeeding. However, the possible association between these drugs and thrombocytopenia and hepatotoxicity indicates that close monitoring of the infant is necessary. Gabapentin has been reported to cross into breast milk at almost 100% of the maternal levels and is, therefore, not recommended for use in breastfeeding women. Little information exists on the use of lamotrigine and topiramate, so caution is advised.|
1. Marchetti F, Romero M, Bonati M, et al. Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Eur J Clin Pharmacol 1993;45:495-501. PubMed Abstract
2. Altshuler L, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606. PubMed Abstract
3. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994;8:461-475. PubMed Abstract
4. Crombie DL, Pinsent RJ, Slater BC, et al. Teratogenic drugs—Royal College of General Practitioners Survey. BMJ 1970;4:178-179. PubMed Citation
5. Kuenssberg EV, Knox JD. Teratogenic effect of anticonvulsants. Lancet 1973;1:198. PubMed Citation
6. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-1542. PubMed Abstract
7. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: An epidemiological reassessment. Compr Psychiatry 1984;25:32-37. Abstract Full Text
8. Patton SW, Misri S, Corral MR, et al. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: Evaluating the risk. Can J Psychiatry 2002;47:959-965. PubMed Abstract
9. Cohen LS, Friedman JM, Jefferson JW, et al. A re-evaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150. PubMed Abstract
10. Iqbal MM. The effects of valproic acid on fetuses, neonates, and nursing infants. Psychiatr Ann 2000;30:221-227.
11. Goldstein DJ, Corbin LA, Fung MC. Olanzapine exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000;20:399-403. PubMed Abstract
12. Barnas C, Bergant A, Hummer M, et al. Clozapine concentration in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994;151:945. PubMed Citation
13. Hale TW. Medications and Mothers’ Milk. 9th ed. Amarillo, TX: Pharmasoft Medical Publishing; 2000.
14. Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998;59(suppl 6):57-64. PubMed Abstract
15. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Clin Psychopharmacol 1998;18:167-169. PubMed Abstract
Kristin Sivertz, MD, FRCPC, Xanthoula Kostaras, BSc
Dr Sivertz is head of the Department of Psychiatry, Providence Health Care, and associate dean of Postgraduate Medical Education at UBC. Ms Kostaras is a research assistant in the Reproductive Mental Health program at BC Women’s Hospital and St. Paul’s Hospital.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org